Follow this innovation
[ via 
] [?]
Novel drugs targeting metastatic cancers
Children's Hospital Boston
posted on 02/16/2010
Dr. Zetter and colleagues developed a four-step screen that relies on differential cytotoxicity of drugs for highly metastatic cells to identify novel therapeutic agents for late-stage cancer. From a library of 1120 non-toxic FDA-approved drugs, benzimidazoles were identified as a class of compounds that are preferentially active against highly metastatic prostate tumor cells and exhibit minimal cell kill in normal cells was selected. These drugs showed synergistic anti-tumor activity with paclitaxel, displayed cytotoxic activity in paclitaxel-resistant prostate cancer cells and prolonged survival of animals with disseminated prostate cancer by an average of 51% when administered after lung metastatic colonies were established. Dr. Zetter and colleagues also designed alternative formulations of these drugs to enhance further the anti-metastatic effect. This project is a recipient of a CHB Technology Development Fund award in 2010.
File Number: CMCC 1653
Other Information: *Investigator(s)*
Bruce Zetter
*Contact*
Maude Tessier, Maude.Tessier@childrens.harvard.edu
This innovation currently is not available for online licensing. Please contact David Altman at Children's Hospital Boston for more information.
request more info
ProfileFind more innovations
